Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06048094 · ClinicalTrials.gov registry record · Phase 1
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
A Phase 1 study of Brain Metastases and Brain Cancer, sponsored by Baptist Health South Florida.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06048094 is a Phase 1 study of Brain Metastases and Brain Cancer that is actively recruiting participants, run by Baptist Health South Florida. The registered enrollment target is 46 participants, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06048094, a Phase 1 study of Brain Metastases and Brain Cancer, is actively recruiting participants, sponsored by Baptist Health South Florida.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis after SRS.
Conditions Studied
Interventions
- DRUG 18F fluciclovine
Study Locations (1)
Florida
- Miami Cancer Institute - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-04-11 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06048094
The ClinicalTrials.gov registry entry for NCT06048094 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (78% lower). The listed sponsor is Baptist Health South Florida, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which 18F fluciclovine is the first listed.
NCT06048094 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06048094 about?
NCT06048094 is a clinical study titled "18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery". This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis afte...
What is the current status of trial NCT06048094?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2024-04-11. Estimated completion is 2027-05.
What conditions does trial NCT06048094 study?
This clinical trial studies the following conditions: Brain Metastases, Brain Cancer, Brain Metastases, Adult.
What interventions are being tested in trial NCT06048094?
The interventions under investigation include: 18F fluciclovine (DRUG).
Who is sponsoring clinical trial NCT06048094?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06048094 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
RECRUITING · Phase 1
-
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
RECRUITING · Phase 1
-
Phase I Study of Fractionated Stereotactic Radiation Therapy
RECRUITING · Phase 1
-
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
RECRUITING · Phase 1
-
Stereotactic Radiosurgery Dose Escalation for Brain Metastases
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.